Phylogica Limited

The Mccomb Foundation, Inc.

Paul Michael Watt

Richard Hopkins

Wayne Robert Thomas

Katrin Hoffman

Roland L Dunbrack

Mark Fear

Nadia Milech

Deborah Strickland

Nadia Marian Dorothy Milech

Patrick G Holt

Nadia Marian Milech

The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.

Method of determining, identifying or isolating cell-penetrating peptides

The present invention provides the means for producing libraries of peptide structures for drug screening applications that are capable of folding or assuming their native conformations independently of artificial scaffolds or flanking sequences in the proteins from which they are derived. The libraries can be highly diverse such that they are representative of the repertoire of protein structures existing in nature. The libraries can also be non-redundant or normalized such that the bias towards specific structures existing in source data sets and/or in nature is/are removed. In a particularly preferred embodiment, the present invention provides 30,000 independent fold structures produced by this method. The present invention also provides computer-readable media and systems comprising structural data in relation to the peptide libraries, and methods for displaying and screening the libraries.

Methods of constructing and screening libraries of peptide structures

The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound.

Compositions and uses thereof for the treatment of wounds

Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.

Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith

The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.

CD40-L Inhibitory Peptides

The present invention provides AP-1 signaling inhibitory peptides of SEQ ID NOS:54-57, compositions of the peptides, and methods of treatment of neurological disorders by administration of the peptide(s) or compositions.

Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor

The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid.

Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom

The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid fragments of the libraries are derived from two or more diverse characterized genomes.

Methods of constructing and screening diverse expression libraries

The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and or immunogenicity, said method comprising the step of:

Growing community of inventors

Mount Claremont, Australia

Paul Michael Watt